Category: biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, occupying the top scientific research place at Sanofi.Quigley

.Sanofi has created a late access to the radioligand party, paying for 100 million europeans ($ 110 million) upfront for global civil liberties to a

.Sanofi has actually ceased a phase 2 hardship of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 prevention hardship from its

.Sangamo Therapeutics has actually recognized a quick way to market for its own Fabry health condition candidate, aligning with the FDA on a process that

.Sage Rehabs’ most recent effort to shrink its pipe and labor force will certainly see a 3rd of the biotech’s staff members heading for the

.Matt Gline is actually back with a brand-new ‘vant’ company, after the Roivant Sciences chief executive officer spent Bayer $14 thousand ahead of time for

.After developing a gene therapy collaboration with Dyno Rehabs in 2020, Roche is back for more.In a new offer likely worth much more than $1

.Roche is holding out chances that its own injectable weight problems prospect could ultimately display 25% fat burning in late-stage tests, the pharma’s mind of

.Roche has sent back the legal rights to UCB’s anti-tau antitoxin bepranemab, walking away from a $120 million bet on the Alzheimer’s illness drug prospect

.Roche’s severe cough course has faltered to a stop. The drugmaker, which axed the program after the medicine candidate disappointed in period 2, revealed (PDF)